|
|
托伐普坦联合托拉塞米治疗重症心力衰竭伴稀释性低钠血症的疗效及血液指标、心功能的影响观察
|
Abstract:
目的：重症心力衰竭伴发稀释性低钠血症应用托伐普坦与托拉塞米联合治疗效果、心功能及血液指标分析。方法：选取2017年11月至2018年11月本院诊治120例重症心力衰竭伴发稀释性低钠血症患者，随机分两组，对照组予托拉塞米，研究组予托伐普坦与托拉塞米联合方案，分析两组患者临床疗效、心功能及血液指标情况。结果：(1) 对照组心力衰竭的治疗有效率是83.33%，较研究组的96.67%低，差异具统计学意义(P < 0.05)；对照组稀释性低钠血症的临床有效率为85.00%，较研究组的96.67%低，差异具统计学意义(P < 0.05)。(2) 治疗后，研究组LVESd (32.52 ± 3.49) mm、LVEDd (40.29 ± 4.31) mm比对照组低，LVEF (8.06 ± 6.52)%比对照组高(P < 0.05)；研究组血钠(143.06 ± 2.23) mmol/L、血浆渗透压比对照组高，BNP比对照组低(P < 0.05)。(3) 两组患者治疗前的生活质量评分对比，无统计学差异，P > 0.05；但是经过治疗后两组的生活质量平均均较治疗前有显著提升，但是研究组患者提升的幅度显著高于对照组，差异显著，有统计学意义(P < 0.05)。结论：重症心力衰竭伴发稀释性低钠血症应用托伐普坦与托拉塞米联合治疗，不仅能够改善患者的心功能指标水平和血液指标水平，而且还能大幅度提高患者的生活质量，进而获得满意的治疗效果，次疗法值得在临床中积极推广运用。
Objective: To observe the efficacy of Tolvaptan combined with Torsemide in the treatment of pa-tients with severe heart failure complicated by dilute hyponatremia, and its effects on cardiac function and blood parameters. Methods: A total of 120 patients with severe heart failure compli-cated by dilute hyponatremia who had received treatment in the Hospital between November 2017 and November 2018 were enrolled. They were randomly divided into two groups, with the control group given Torasemide and the study group given Tolvaptan combined with Torasemide. The clinical efficacy, cardiac function and blood parameters in the two groups were analyzed. Results: (1) The effective rate of treatment of heart failure in control group was 83.33%, which was lower than that of study group (96.67%). The difference was statistically significant (P < 0.05). The clinical effective rate of dilute hyponatremia in the control group was 85.00%, which was lower than the study group’s 96.67%, and the difference was statistically significant (P < 0.05). (2) After treatment, LVESd (32.52 ± 3.49) mm and LVEDd (40.29 ± 4.31) mm of the study group were lower than the control group, LVEF (8.06 ± 6.52)% was higher than the control group (P < 0.05); the study group blood sodium (143.06 ± 2.23) mmol/L, plasma osmotic pressure was higher than that of the control group, and BNP was lower than the control group (P < 0.05). (3) There was no significant difference in the quality of life scores between the two groups before treatment, P > 0.05. However, the quality of life of the two groups was significantly higher than that before treatment, but the increase range of the patients in the study group was significantly higher than that of the control group. The difference was statistically significant (P < 0.05). Conclusion: The combination of tolvaptan and torsemide in the treatment of severe heart failure
| [1] | 李军锋, 梁晶. 口服托伐普坦对急性失代偿性心力衰竭合并低钠血症的疗效及安全性研究[J]. 中国药物与临床, 2019, 19(8): 1349-1350. |
| [2] | 胡武明, 施振华, 叶士勇, 等. 托伐普坦片治疗心力衰竭伴收缩功能障碍的临床研究[J]. 中国临床药理学杂志, 2019, 35(7): 617-619. |
| [3] | 王立立, 韩爽, 张至, 等. 不同剂量托伐普坦治疗老年慢性心力衰竭伴利尿剂抵抗患者的疗效与安全性观察[J]. 中华老年心脑血管病杂志, 2019, 21(4): 375-378. |
| [4] | Kaneko, H., Hoelschermann, F., Tambor, G., et al. (2019) Impact of N-Terminal Pro-B-Type Natriu-retic Peptide Response on Long-Term Prognosis after Transcatheter Aortic Valve Implantation for Severe Aortic Stenosis and Heart Failure. Heart and Vessels, 34, 536-543. https://doi.org/10.1007/s00380-018-1297-z |
| [5] | 王毅, 杨征. 托伐普坦和沙库巴曲缬沙坦钠片对慢性心力衰竭患者心功能及血清钠水平的影响研究[J]. 陕西医学杂志, 2019, 48(4): 470-472. |
| [6] | 孟珠. 慢性心力衰竭患者呼吸困难、抑郁情绪与生活质量的关系[D]: [硕士学位论文]. 济南: 山东大学, 2012. |
| [7] | Schmidt, T. and Frerker, C. (2019) Treatment Challenges in Patients with Acute Heart Failure and Severe Aortic Valve Stenosis. Current Cardiology Reports, 21, 1-8. https://doi.org/10.1007/s11886-019-1135-7 |
| [8] | Vikmane, M., Kalējs, O., Kamzola, G., et al. (2018) Assessment of Cardiac Resynchronisation Therapy Efficacy Determining Factors for Patients with Moderate and Severe Heart Failure in the Population of Latvia in a 12 and 24 Month Study. Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences, 72, 313-321. https://doi.org/10.2478/prolas-2018-0049 |
| [9] | 李柏林, 邹育明, 梁明俊, 等. 重组人脑利钠肽联合托伐普坦治疗青中年急性心肌梗死合并心力衰竭的临床观察[J]. 广东医科大学学报, 2018, 36(6): 660-663. |
| [10] | Kanwar, M., Khoo, C., Lohmueller, L., et al. (2019) Predicting Post LVAD Acute Severe Right Heart Failure Using Bayesian Analysis. Journal of Heart and Lung Transplantation, 38, S357-S357. https://doi.org/10.1016/j.healun.2019.01.907 |
| [11] | 庞国珍, 黄志敏, 陈伟婵, 等. 托伐普坦联合常规治疗慢性心力衰竭(CHF)并低钠血症的效果分析[J]. 齐齐哈尔医学院学报, 2018, 39(23): 2753-2755. |
| [12] | Mateescu, A.D., C？lin, A., Beladan, C.C., et al. (2019) Left Atrial Dysfunction as an Independent Correlate of Heart Failure Symptoms in Patients with Severe Aortic Stenosis and Preserved Left Ventricular Ejection Fraction. Journal of the American Society of Echocardiography, 32, 257-266. https://doi.org/10.1016/j.echo.2018.11.007 |
| [13] | Orea-Tejeda, A., Navarrete-Pe？aloza, A.G., Verdeja-Vendrell, L., et al. (2018) Right Heart Failure as a Risk Factor for Severe Exacerbation in Patients with Chronic Obstructive Pulmonary Disease: Prospective Cohort Study. The Clinical Respiratory Journal, 12, 2635-2641. https://doi.org/10.1111/crj.12969 |
| [14] | Kuang, H., Zhou, X., Li, L., Yi, Q.J., et al. (2018) Early Severe Coronary Heart Disease and Ischemic Heart Failure in Homozygous Familial Hypercholesterolemia: A Case Report. Medicine, 97, e12869. https://doi.org/10.1097/MD.0000000000012869 |
| [15] | 王茜, 杨小东, 刘东霞, 等. 托伐普坦与托拉塞米治疗重症心力衰竭伴稀释性低钠血症的效果比较[J]. 河北医药, 2018, 40(23): 3582-3585. |
| [16] | 李广. 托伐普坦与托拉塞米治疗慢性心衰急性发作的临床效果观察[J]. 名医, 2018(11): 214. |
| [17] | 白晓黎. 托伐普坦与托拉塞米对慢性心衰急性发作的治疗效果对比研究[J]. 首都食品与医药, 2018, 25(18): 50. |
| [18] | 隋利军, 李维, 甘建祥, 等. 托伐普坦对慢性心力衰竭急性发作合并利尿剂抵抗的疗效研究[J]. 国际心血管病杂志, 2018, 45(3): 186-188. |
| [19] | 刘婷, 孙爱梅, 陈还珍. 托伐普坦联合托拉塞米治疗老年心力衰竭的短期疗效[J]. 中华临床医师杂志(电子版), 2017, 11(21): 2357-2361. |
| [20] | 杨小东, 王茜, 刘东霞, 等. 托伐普坦与托拉塞米治疗重症心力衰竭伴稀释性低钠血症的疗效分析[J]. 河北医药, 2018, 40(21): 3303-3305+3309. |
| [21] | 张丽, 陈伟. 托伐普坦与托拉塞米在慢性心力衰竭急性发作患者中的疗效对比[J]. 中国循证心血管医学杂志, 2017, 9(10): 1182-1184. |
| [22] | 贺仙光. 托伐普坦联合托拉塞米治疗老年难治性心衰的疗效观察[J]. 中国社区医师, 2017, 33(24): 39+41. |
| [23] | 陈曦, 解珍, 姜妤, 等. 托伐普坦与托拉塞米治疗重症心力衰竭伴稀释性低钠血症临床疗效的对比研究[J]. 实用心脑肺血管病杂志, 2017, 25(4): 67-69. |
| [24] | 胡玲玲, 任江华. 托伐普坦与托拉塞米治疗慢性心衰急性发作的疗效比较[J]. 西南国防医药, 2017, 27(4): 338-340. |
